The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Giving AXL the axe: targeting AXL in human malignancy
Open accessAbstract
The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunologic response. Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematologic and solid malignancies, including acute myeloid leukaemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers. In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumour angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response. As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies. Several AXL inhibitors are currently in preclinical and clinical development. This article reviews the structure, regulation, and function of AXL; the role of AXL in the tumour microenvironment; the development of AXL as a therapeutic target; and areas of ongoing and future investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Comprehensive genomic characterization of head and neck squamous cell carcinomas
The Cancer Genome Atlas Network (2015) · Nature · doi:10.1038/nature14129 · Cited by 3,877
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.033 · Cited by 1,858
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Self-citationTAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response
Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. A., & Lemke, G. (2007) · Cell · doi:10.1016/j.cell.2007.10.034 · Cited by 1,055
O'Bryan, J. P., Frye, R. A., Cogswell, P. C., Neubauer, A., Kitch, B., Prokop, C., Espinosa, R., Le Beau, M. M., Earp, H. S., & Liu, E. T. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5016 · Cited by 742
Stitt, T. N., Conn, G., Goret, M., Lai, C., Bruno, J., Radzlejewski, C., Mattsson, K., Fisher, J., Gies, D. R., Jones, P. F., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90520-0 · Cited by 730
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Graham, D. K., DeRyckere, D., Davies, K. D., & Earp, H. S. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3847 · Cited by 698
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639
The transcriptional landscape and mutational profile of lung adenocarcinoma
Seo, J.-S., Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, J. K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J.-O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 584
Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums
Ravichandran, K. S. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20101157 · Cited by 549
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 535
Mak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez-Canales, J., Wistuba, I. I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0876 · Cited by 535
Self-citationExpression Analysis Highlights AXL as a Candidate Zika Virus Entry Receptor in Neural Stem Cells
Nowakowski, T. J., Pollen, A. A., Di Lullo, E., Sandoval-Espinosa, C., Bershteyn, M., & Kriegstein, A. R. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.03.012 · Cited by 529
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL
Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., Halsey, W., Sathe, G. M., Martin, A.-M., & Gilmer, T. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4490 · Cited by 495
Varnum, B. C., Young, C., Elliott, G., Garcia, A., Bartley, T. D., Fridell, Y.-W., Hunt, R. W., Trail, G., Clogston, C., Toso, R. J., et al. (1995) · Nature · doi:10.1038/373623a0 · Cited by 481
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A. M., Langdon, W. Y., Ikeda, F., Fededa, J. P., et al. (2014) · Nature · doi:10.1038/nature12998 · Cited by 456
Diversification of TAM receptor tyrosine kinase function
Zagórska, A., Través, P. G., Lew, E. D., Dransfield, I., & Lemke, G. (2014) · Nature Immunology · doi:10.1038/ni.2986 · Cited by 430
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
Zhou, L., Liu, X.-D., Sun, M., Zhang, X., German, P., Bai, S., Ding, Z., Tannir, N., Wood, C. G., Matin, S. F., et al. (2016) · Oncogene · doi:10.1038/onc.2015.343 · Cited by 395
Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.010 · Cited by 325 · cited 3×
“…scenarios as increasing apoptosis in glioblastoma (Onken et al, 2016), sensitising tumours to PARP inhibition (Balaji et al, 2017), overcoming resistance to PI3K inhibitors (Elkabets et al, 2015) and synergising with anthracycline treatment in breast cancer models (Wang et al, 2016), among others.”
BackgroundKhoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C., Baccarani, M., Kim, D.-W., Zaritskey, A., Countouriotis, A., Besson, N., Leip, E., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390120 · Cited by 324
Flavivirus Entry Receptors: An Update
Perera-Lecoin, M., Meertens, L., Carnec, X., & Amara, A. (2013) · Viruses · doi:10.3390/v6010069 · Cited by 323
Asiedu, M. K., Beauchamp-Perez, F. D., Ingle, J. N., Behrens, M. D., Radisky, D. C., & Knutson, K. L. (2014) · Oncogene · doi:10.1038/onc.2013.57 · Cited by 303
Structural basis for Gas6–Axl signalling
Sasaki, T., Knyazev, P. G., Clout, N. J., Cheburkin, Y., Göhring, W., Ullrich, A., Timpl, R., & Hohenester, E. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600912 · Cited by 303
Meyer, A. S., Miller, M. A., Gertler, F. B., & Lauffenburger, D. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004155 · Cited by 284
Mahadevan, D., Cooke, L., Riley, C., Swart, R., Simons, B., Della Croce, K., Wisner, L., Iorio, M., Shakalya, K., Garewal, H., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210173 · Cited by 282
Expression of Axl in Lung Adenocarcinoma and Correlation with Tumor Progression
Shinh, Y.-S., Lai, C.-Y., Kao, Y.-R., Shiah, S.-G., Chu, Y.-W., Lee, H.-S., & Wu, C.-W. (2005) · Neoplasia · doi:10.1593/neo.05640 · Cited by 273
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Rankin, E. B., Fuh, K. C., Castellini, L., Viswanathan, K., Finger, E. C., Diep, A. N., LaGory, E. L., Kariolis, M. S., Chan, A., Lindgren, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404848111 · Cited by 269
A novel putative tyrosine kinase receptor with oncogenic potential.
Janssen, J. W. G., Schulz, A. S., Steenvoorden, A. C. M., Schmidberger, M., Strehl, S., Ambros, P. F., & Bartram, C. R. (1991) · PubMed · Cited by 254
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
Mudduluru, G., Ceppi, P., Kumarswamy, R., Scagliotti, G. V., Papotti, M., & Allgayer, H. (2011) · Oncogene · doi:10.1038/onc.2011.13 · Cited by 252
Twist mediates suppression of inflammation by type I IFNs and Axl
Sharif, M. N., Šošić, D., Rothlin, C. V., Kelly, E., Lemke, G., Olson, E. N., & Ivashkiv, L. B. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051725 · Cited by 251
Ye, X., Li, Y., Stawicki, S., Couto, S., Eastham-Anderson, J., Kallop, D., Weimer, R., Wu, Y., & Pei, L. (2010) · Oncogene · doi:10.1038/onc.2010.268 · Cited by 232
Hong, C.-C., Lay, J.-D., Huang, J.-S., Cheng, A.-L., Tang, J.-L., Lin, M.-T., Lai, G.-M., & Chuang, S.-E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.017 · Cited by 232
Axl is essential for VEGF‐A‐dependent activation of PI3K/Akt
Ruan, G., & Kazlauskas, A. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.21 · Cited by 223
Ben-Batalla, I., Schultze, A., Wroblewski, M., Erdmann, R., Heuser, M., Waizenegger, J. S., Riecken, K., Binder, M., Schewe, D., Sawall, S., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491431 · Cited by 217
Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor
Sainaghi, P. P., Castello, L., Bergamasco, L., Galletti, M., Bellosta, P., & Avanzi, G. C. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20265 · Cited by 209
Koorstra, J.-B. M., Karikari, C., Feldmann, G., Bisht, S., Leal-Rojas, P., Offerhaus, G. J. A., Alvarez, H., & Maitra, A. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.7.7923 · Cited by 205
AXL Mediates Resistance to Cetuximab Therapy
Brand, T. M., Iida, M., Stein, A. P., Corrigan, K. L., Braverman, C. M., Luthar, N., Toulany, M., Gill, P. S., Salgia, R., Kimple, R. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0294 · Cited by 198
GAS6 Induces Axl-mediated Chemotaxis of Vascular Smooth Muscle Cells
Fridell, Y.-W. C., Villa, J., Attar, E. C., & Liu, E. T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.12.7123 · Cited by 195
The Receptor Tyrosine Kinase ARK Mediates Cell Aggregation by Homophilic Binding
Bellosta, P., Costa, M., Lin, D. A., & Basilico, C. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.614 · Cited by 183
Ruan, G.-X., & Kazlauskas, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.474619 · Cited by 181
Fridell, Y.-W. C., Jin, Y., Quilliam, L. A., Burchert, A., McCloskey, P., Spizz, G., Varnum, B., Der, C., & Liu, E. T. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.1.135 · Cited by 177
Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis
Neubauer, A., Fiebeler, A., Graham, D., O'Bryan, J., Schmidt, C., Barckow, P., Serke, S., Siegert, W., Snodgrass, H., & Huhn, D. (1994) · Blood · doi:10.1182/blood.v84.6.1931.1931 · Cited by 176
Braunger, J., Schleithoff, L., Schulz, A. S., Kessler, H., Lammers, R., Ullrich, A., Bartram, C. R., & Janssen, J. W. (1997) · Oncogene · doi:10.1038/sj.onc.1201123 · Cited by 171
Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1
Tai, K.-Y., Shieh, Y.-S., Lee, C.-S., Shiah, S.-G., & Wu, C.-W. (2008) · Oncogene · doi:10.1038/onc.2008.57 · Cited by 168
Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian Cancer
Macleod, K., Mullen, P., Sewell, J. M., Rabiasz, G. J., Lawrie, S. S., Miller, E. P., Smyth, J. F., & Langdon, S. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2684 · Cited by 167
Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer
Bosurgi, L., Bernink, J. H., Cuevas, V. D., Gagliani, N., Joannas, L. D., Schmid, E. T., Booth, C. J., Ghosh, S., & Rothlin, C. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302507110 · Cited by 160
TAZ Expression as a Prognostic Indicator in Colorectal Cancer
Yuen, H.-F., McCrudden, C. M., Huang, Y.-H., Tham, J. M., Zhang, X., Zeng, Q., Zhang, S.-D., & Hong, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054211 · Cited by 158
Wang, C., Jin, H., Wang, N., Fan, S., Wang, Y., Zhang, Y., Lin, W., Tao, X., Gu, D., Zhao, F., et al. (2016) · Theranostics · doi:10.7150/thno.15083 · Cited by 150
Toledo, R. A., Qin, Y., Cheng, Z.-M., Gao, Q., Iwata, S., Silva, G. M., Prasad, M. L., Ocal, I. T., Rao, S. N., D, N. A. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1841 · Cited by 147
Paccez, J. D., Vasques, G. J., Correa, R. G., de Vasconcellos, J. F., Duncan, K., Gu, X., Bhasin, M., Libermann, T. A., & Zerbini, L. F. (2012) · Oncogene · doi:10.1038/onc.2012.89 · Cited by 145
Mudduluru, G., Vajkoczy, P., & Allgayer, H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0326 · Cited by 135
Weinger, J. G., Brosnan, C. F., Loudig, O., Goldberg, M. F., Macian, F., Arnett, H. A., Prieto, A. L., Tsiperson, V., & Shafit-Zagardo, B. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-49 · Cited by 134
Expression of Receptor Tyrosine Kinase Axl and its Ligand Gas6 in Rheumatoid Arthritis
O’Donnell, K., Harkes, I. C., Dougherty, L., & Wicks, I. P. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65369-2 · Cited by 132
The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung
Fujimori, T., Grabiec, A. M., Kaur, M., Bell, T. J., Fujino, N., Cook, P. C., Svedberg, F. R., MacDonald, A. S., Maciewicz, R. A., Singh, D., et al. (2015) · Mucosal Immunology · doi:10.1038/mi.2014.129 · Cited by 132
Lee, H., Jeng, Y., Chen, Y., Chung, L., & Yuan, R. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt372 · Cited by 131
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Brand, T. M., Iida, M., Stein, A. P., Corrigan, K. L., Braverman, C. M., Coan, J. P., Pearson, H. E., Bahrar, H., Fowler, T. L., Bednarz, B. P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2648 · Cited by 127
Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells
Dufies, M., Jacquel, A., Belhacène, N., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.360 · Cited by 119
Gallicchio, M., Mitola, S. M. F., Valdembri, D., Fantozzi, R., Varnum, B. C., Avanzi, G. C., & Bussolino, F. (2004) · Blood · doi:10.1182/blood-2004-04-1469 · Cited by 115
Mackiewicz, M., Huppi, K. E., Pitt, J. J., Dorsey, T. H., Ambs, S., & Caplen, N. J. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1690-0 · Cited by 115
Lay, J., Hong, C., Huang, J.-S., Yang, Y.-Y., Pao, C.-Y., Liu, C.-H., Lai, Y.-P., Lai, G., Cheng, A., Su, I., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3191 · Cited by 114
Han, J., Tian, R., Yong, B., Luo, C., Tan, P., Shen, J., & Peng, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.019 · Cited by 109
Vouri, M., Croucher, D. R., Kennedy, S. P., An, Q., Pilkington, G. J., & Hafizi, S. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.66 · Cited by 106
Balaji, K., Vijayaraghavan, S., Diao, L., Tong, P., Fan, Y.-H., Carey, J. P. W., Bui, T. N., Warner, S. L., Heymach, J. V., Hunt, K. K., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0157 · Cited by 103
Self-citationMudduluru, G., & Allgayer, H. (2008) · Bioscience Reports · doi:10.1042/bsr20080046 · Cited by 98
AXL regulates mesothelioma proliferation and invasiveness
Ou, W.-B., Corson, J. M., Flynn, D. L., Lu, W.-P., Wise, S., Bueno, R., Sugarbaker, D. J., & Fletcher, J. A. (2010) · Oncogene · doi:10.1038/onc.2010.555 · Cited by 97
Ishikawa, M., Sonobe, M., Nakayama, E., Kobayashi, M., Kikuchi, R., Kitamura, J., Imamura, N., & Date, H. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2795-3 · Cited by 93
Wang, X., Saso, H., Iwamoto, T., Xia, W., Gong, Y., Pusztai, L., Woodward, W. A., Reuben, J. M., Warner, S. L., Bearss, D. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0967 · Cited by 89
Cichoń, M. A., Szentpétery, Z., Caley, M. P., Papadakis, E. S., Mackenzie, I. C., Brennan, C. H., & O’Toole, E. A. (2013) · Oncogene · doi:10.1038/onc.2013.388 · Cited by 75
Determinants for transformation induced by the Axl receptor tyrosine kinase
Burchert, A., Attar, E. C., McCloskey, P., Fridell, Y.-W. C., & Liu, E. T. (1998) · Oncogene · doi:10.1038/sj.onc.1201865 · Cited by 65
Axl Is a Prognostic Marker in Oral Squamous Cell Carcinoma
Lee, C., Yen, C.-Y., Liu, S.-Y., Chen, C.-K., Chiang, C., Shiah, S., Chen, P.-H., & Shieh, Y. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1985-8 · Cited by 62
Onken, J., Torka, R., Korsing, S., Radke, J., Krementeskaia, I., Nieminen-Kelhä, M., Bai, X., Ullrich, A., Heppner, F. L., & Vajkoczy, P. (2016) · Oncotarget · doi:10.18632/oncotarget.7130 · Cited by 59
Cui, Z.-L., Han, F.-F., Peng, X.-H., Chen, X., Luan, C.-Y., Han, R.-C., Xu, W.-G., & Guo, X.-J. (2012) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201202500416 · Cited by 56
KIM, K.-C., Baek, S., & Lee, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3216 · Cited by 55
Ott, M., Litzenburger, U. M., Sahm, F., Rauschenbach, K. J., Tudoran, R., Hartmann, C. J., Márquez, V. E., von Deimling, A., Wick, W., & Platten, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047663 · Cited by 55
The AXL Receptor Is a Sensor of Ligand Spatial Heterogeneity
Meyer, A. S., Zweemer, A. J. M., & Lauffenburger, D. A. (2015) · Cell Systems · doi:10.1016/j.cels.2015.06.002 · Cited by 54
TAM receptors in apoptotic cell clearance, autoimmunity, and cancer
Nguyen, K.-Q. N., Tsou, W., Kotenko, S. V., & Birge, R. B. (2013) · Autoimmunity · doi:10.3109/08916934.2013.794515 · Cited by 53
Hsieh, M., Yang, P., Wong, L.-F., & Lee, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9231 · Cited by 52
Heckmann, D., Maier, P., Laufs, S., Li, L., Sleeman, J. P., Trunk, M. J., Leupold, J. H., Wenz, F. K., Zeller, W. J., Früehauf, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0582 · Cited by 49
Mudduluru, G., Leupold, J. H., Ströbel, P., & Allgayer, H. (2010) · Biology of the Cell · doi:10.1042/bc20100094 · Cited by 47
Impact of Expression of Vimentin and Axl in Breast Cancer
Tanaka, K., Tokunaga, E., Inoue, Y., Yamashita, N., Saeki, H., Okano, S., Kitao, H., Oki, E., Oda, Y., & Maehara, Y. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.06.015 · Cited by 43
Li, N., Liu, Z., Zhang, Y., Chen, Q., Liu, P., Cheng, C. Y., Lee, W. M., Chen, Y., & Han, D. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.97 · Cited by 34
Zhang, Y., Tang, Y.-J., Man, Y., Pan, F., Li, Z.-H., & Jia, L.-S. (2013) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201302600117 · Cited by 30
le Boulch, N. L., Truong‐Ngoc, N. A., Gauchy, C., & Besson, M. (1991) · Brain Research · doi:10.1016/0006-8993(91)90003-e · Cited by 26
Lozneanu, L., Pinciroli, P., Ciobanu, D. A., Carcangiu, M. L., Canevari, S., Tomassetti, A., & Căruntu, I.-D. (2016) · PubMed · Cited by 26
Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response
Read, S. A., Tay, E. S. E., Shahidi, M., O'Connor, K. S., Booth, D. R., George, J., & Douglas, M. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136227 · Cited by 24
Cited by
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Zhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 488
Lim, S. M., Syn, N. L., Cho, B. C., & Soo, R. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.006 · Cited by 288
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Li, H., Liu, Z., Liu, L., Zhang, H., Han, C., Girard, L., Park, H., Zhang, A., Dong, C., Ye, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100554 · Cited by 102
Metadata
- Authors
- Gay, C. M., Balaji, K., & Byers, L. A.
- Venue
- British Journal of Cancer
- Published
- 2017-01-10
- Volume
- 116
- Issue
- 4
- Pages
- 415-423
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2568917916
- Cited by
- 334
- References
- 91
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.